ID

27683

Description

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

Keywords

Versions (2)
  1. 11/15/17 11/15/17 -
  2. 11/26/17 11/26/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

November 26, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Serious adverse events GSK study Prostatic neoplasms NCT00883909

English

Serious adverse events GSK study Prostatic neoplasms NCT00883909

1 forms  
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
Subject Identifier
Description

Subject Identifier

Data type

integer

Alias
UMLS CUI [1]
C2348585
Centre Number
Description

Centre Number

Data type

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0019994
SERIOUS ADVERSE EVENT (SAE)
Description

SERIOUS ADVERSE EVENT (SAE)

Alias
UMLS CUI-1
C1519255
Did the subject experience a serious adverse event during the study?
Description

If Yes, record details below.

Data type

text

Alias
UMLS CUI [1]
C1519255
If fatal, was a post-mortem/autopsy performed?
Description

If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.

Data type

text

Alias
UMLS CUI [1]
C0004398
SECTION 1: Serious adverse event
Description

SECTION 1: Serious adverse event

Alias
UMLS CUI-1
C1519255
Event
Description

Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page.

Data type

text

Alias
UMLS CUI [1]
C0877248
Start Date
Description

Record the start date of the first occurrence of the SAE.

Data type

date

Alias
UMLS CUI [1]
C0808070
Outcome
Description

All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.

Data type

integer

Alias
UMLS CUI [1]
C1705586
End Date
Description

Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.

Data type

date

Alias
UMLS CUI [1]
C0806020
Maximum Intensity
Description

Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Mild= An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate=An event that is sufficiently discomforting to interfere with normal everyday activities. Severe= An event that prevents normal everyday activities. Not applicable=those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).

Data type

text

Alias
UMLS CUI [1]
C0518690
Action Taken with IP in REDUCE Study or Prescription Dutasteride as a Result of the SAE
Description

IP in REDUCE study or prescription dutasteride withdrawn = Administration of IP in REDUCE study or prescription dutasteride was permanently discontinued. Dose reduced = Dose is reduced for IP in REDUCE study or prescription dutasteride. Dose increased = Dose increased for IP in REDUCE study or prescription dutasteride. Dose not changed = IP in REDUCE study or prescription dutasteride continues even though an adverse event has occurred. Dose interrupted = Administration of IP in REDUCE study or prescription dutasteride was temporarily interrupted but then restarted. Not applicable =Subject was not receiving IP in REDUCE study or prescription dutasteride when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).

Data type

text

Alias
UMLS CUI [1,1]
C2826626
UMLS CUI [1,2]
C2830183
Did the subject withdraw from study as a result of this SAE?
Description

Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’.

Data type

text

Alias
UMLS CUI [1]
C0422727
Is there a reasonable possibility the SAE may have been caused by IP in REDUCE study or prescription dutasteride?
Description

It is a regulatory requirement for investigators to assess relationship to investigational product in REDUCE study or prescription dutasteride based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

Data type

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C0439849
If Yes, specify reason
Description

reason

Data type

integer

Alias
UMLS CUI [1]
C0566251
SECTION 2: Seriousness (specify reason(s) for considering this a SAE, select all that apply)
Description

SECTION 2: Seriousness (specify reason(s) for considering this a SAE, select all that apply)

Alias
UMLS CUI-1
C1519255
[A] Results in death
Description

SAE results in death

Data type

boolean

Alias
UMLS CUI [1]
C0011065
[B] Is life-threatening
Description

Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

Data type

boolean

Alias
UMLS CUI [1]
C2826244
[C] Requires hospitalisation or prolongation of existing hospitalisation
Description

Note: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.

Data type

boolean

Alias
UMLS CUI [1]
C0019993
[D] Results in disability/incapacity
Description

Note: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

Data type

boolean

Alias
UMLS CUI [1]
C0231170
[E] Congenital anomaly/birth defect
Description

Congenital anomaly/birth defect

Data type

boolean

Alias
UMLS CUI [1]
C0000768
[F] Other
Description

Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.

Data type

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C1880177
[F] Other, specify
Description

See definition of SAE

Data type

text

Alias
UMLS CUI [1]
C3845569
SECTION 3: Demography data
Description

SECTION 3: Demography data

Alias
UMLS CUI-1
C1704791
Date of birth
Description

Date of birth

Data type

date

Alias
UMLS CUI [1]
C0421451
Sex
Description

Sex

Data type

text

Alias
UMLS CUI [1]
C0079399
Weight
Description

Weight

Data type

float

Measurement units
  • kg
Alias
UMLS CUI [1]
C0005910
kg
SECTION 4: Recurrence of SAE
Description

SECTION 4: Recurrence of SAE

Alias
UMLS CUI-1
C0034897
UMLS CUI-2
C1519255
If Investigational Product in REDUCE Study or Prescription Dutasteride was Stopped, Did the Reported Event(s) Recur After Further Investigational Product in REDUCE Study or Prescription Dutasteride was Administered?
Description

If deliberate or inadvertent administration of further dose(s) of investigational product in REDUCE study or prescription dutasteride to the subject occurred, did the reported adverse event recur?

Data type

text

Alias
UMLS CUI [1,1]
C0034897
UMLS CUI [1,2]
C1519255
SECTION 5: Possible Causes of SAE Other Than Investigational Product in REDUCE Study or Prescription Dutasteride
Description

SECTION 5: Possible Causes of SAE Other Than Investigational Product in REDUCE Study or Prescription Dutasteride

Alias
UMLS CUI-1
C0392360
UMLS CUI-2
C1519255
Disease under study
Description

Disease under study

Data type

boolean

Alias
UMLS CUI [1]
C0012634
Medical condition(s)
Description

Medical condition

Data type

boolean

Alias
UMLS CUI [1]
C1699700
Specify medical condition(s)
Description

Medical condition specification

Data type

text

Lack of efficacy
Description

Lack of efficacy

Data type

boolean

Alias
UMLS CUI [1]
C0235828
Withdrawal of investigational product in REDUCE study or prescription dutasteride
Description

Withdrawal of investigational product

Data type

boolean

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0013227
Concomitant Medication(s)
Description

Concomitant Medication

Data type

boolean

Alias
UMLS CUI [1]
C2347852
Specify concomitant medication(s)
Description

Concomitant Medication specification

Data type

text

Alias
UMLS CUI [1]
C2347852
Activity related to study participation (e.g. procedures)
Description

Activity related to study participation

Data type

boolean

Alias
UMLS CUI [1]
C2348568
Other
Description

Other

Data type

boolean

Alias
UMLS CUI [1]
C0205394
Other, specify
Description

Other

Data type

text

Alias
UMLS CUI [1]
C0205394
SECTION 6: RELEVANT Medical Conditions
Description

SECTION 6: RELEVANT Medical Conditions

Alias
UMLS CUI-1
C0262926
Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE.
Description

Relevant Medical Conditions

Data type

text

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0262926
UMLS CUI [1,3]
C1519255
Date of onset
Description

Date of onset

Data type

date

Alias
UMLS CUI [1]
C0574845
Condition Present at Time of the SAE?
Description

continuation SAE

Data type

text

Alias
UMLS CUI [1,1]
C0805733
UMLS CUI [1,2]
C1519255
If No, Date of Last Occurrence
Description

Date of Last Occurrence

Data type

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C2745955
SECTION 7: Other RELEVANT Risk Factors
Description

SECTION 7: Other RELEVANT Risk Factors

Alias
UMLS CUI-1
C0035648
Other relevant risk factors
Description

Provide any family or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE.

Data type

text

Alias
UMLS CUI [1]
C0035648
SECTION 8: RELEVANT Concomitant Medications
Description

SECTION 8: RELEVANT Concomitant Medications

Alias
UMLS CUI-1
C2347852
Drug name
Description

(Trade name preferred)

Data type

text

Alias
UMLS CUI [1]
C0013227
Dose
Description

Dose

Data type

float

Alias
UMLS CUI [1]
C3174092
Unit
Description

Unit

Data type

text

Alias
UMLS CUI [1]
C1519795
Frequency
Description

Frequency

Data type

text

Alias
UMLS CUI [1]
C3476109
Route
Description

Route

Data type

text

Alias
UMLS CUI [1]
C0013153
Taken Prior to Study?
Description

administration prior to study

Data type

text

Alias
UMLS CUI [1]
C2826667
Start Date
Description

Start Date

Data type

date

Alias
UMLS CUI [1]
C0808070
Stop Date
Description

Stop Date

Data type

date

Alias
UMLS CUI [1]
C0806020
Ongoing Medication?
Description

Ongoing Medication

Data type

text

Alias
UMLS CUI [1]
C2826666
Reason for Medication
Description

Reason for Medication

Data type

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0013227
SECTION 9: Drug Details
Description

SECTION 9: Drug Details

Alias
UMLS CUI-1
C0013227
UMLS CUI-2
C1522508
Start Date Investigational Product (from REDUCE study)
Description

Start Date Investigational Product

Data type

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0013230
Stop Date Investigational Product (from REDUCE study)
Description

Stop Date Investigational Product

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0013230
Start Date Prescription Dutasteride
Description

Start Date

Data type

date

Alias
UMLS CUI [1]
C0808070
Stop Date Prescription Dutasteride
Description

Stop Date

Data type

date

Alias
UMLS CUI [1]
C0806020
SECTION 10: Details of RELEVANT Assessments
Description

SECTION 10: Details of RELEVANT Assessments

Alias
UMLS CUI-1
C0220825
Details of Relevant Assessments
Description

Provide details of any other tests/procedures which were carried out to diagnose or confirm the SAE e.g., laboratory data with units and normal range.

Data type

text

Alias
UMLS CUI [1,1]
C1261322
UMLS CUI [1,2]
C1519255
SECTION 11: Narrative Remarks
Description

SECTION 11: Narrative Remarks

Alias
UMLS CUI-1
C0947611
Narrative Remarks
Description

Provide a brief narrative description of the SAE and details of treatment given.

Data type

text

Alias
UMLS CUI [1]
C0947611
Investigator information
Description

Investigator information

Alias
UMLS CUI-1
C1533716
UMLS CUI-2
C0035173
Investigator’s signature
Description

Confirming that the data on the SAE pages are accurate and complete.

Data type

text

Alias
UMLS CUI [1]
C2346576
Investigator’s name (print)
Description

Investigator name

Data type

text

Alias
UMLS CUI [1]
C2826892
Date
Description

Investigator Signature Date

Data type

date

Alias
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Back to the top of the page

Similar models

Serious adverse events GSK study Prostatic neoplasms NCT00883909

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
Subject Identifier
Item
Subject Identifier
integer
C2348585 (UMLS CUI [1])
Centre Number
Item
Centre Number
text
C0600091 (UMLS CUI [1,1])
C0019994 (UMLS CUI [1,2])
Item Group
SERIOUS ADVERSE EVENT (SAE)
C1519255 (UMLS CUI-1)
Item
Did the subject experience a serious adverse event during the study?
text
C1519255 (UMLS CUI [1])
non-serious adverse events
Code List
Did the subject experience a serious adverse event during the study?
CL Item
Yes (Y)
CL Item
No (N)
Item
If fatal, was a post-mortem/autopsy performed?
text
C0004398 (UMLS CUI [1])
fatal SAE
Code List
If fatal, was a post-mortem/autopsy performed?
CL Item
Yes (Y)
CL Item
No (N)
Item Group
SECTION 1: Serious adverse event
C1519255 (UMLS CUI-1)
Event
Item
Event
text
C0877248 (UMLS CUI [1])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Item
Outcome
integer
C1705586 (UMLS CUI [1])
Outcome
Code List
Outcome
CL Item
Recovered/Resolved (1)
C1709863 (UMLS CUI-1)
(Comment:en)
CL Item
Recovering/Resolving (2)
(Comment:en)
CL Item
Not recovered/Not resolved (3)
(Comment:en)
CL Item
Recovered/Resolved with sequelae (4)
(Comment:en)
CL Item
Fatal (5)
C1302234 (UMLS CUI-1)
(Comment:en)
End Date
Item
End Date
date
C0806020 (UMLS CUI [1])
Item
Maximum Intensity
text
C0518690 (UMLS CUI [1])
Maximum Intensity
Code List
Maximum Intensity
CL Item
Mild (1)
C2945599 (UMLS CUI-1)
(Comment:en)
CL Item
Moderate (2)
C0205081 (UMLS CUI-1)
(Comment:en)
CL Item
Severe (3)
C0205082 (UMLS CUI-1)
(Comment:en)
CL Item
Not applicable (X)
C1272460 (UMLS CUI-1)
(Comment:en)
Item
Action Taken with IP in REDUCE Study or Prescription Dutasteride as a Result of the SAE
text
C2826626 (UMLS CUI [1,1])
C2830183 (UMLS CUI [1,2])
Action Taken with IP
Code List
Action Taken with IP in REDUCE Study or Prescription Dutasteride as a Result of the SAE
CL Item
IP in REDUCE study or prescription dutasteride withdrawn (1)
(Comment:en)
CL Item
Dose reduced (2)
C1707814 (UMLS CUI-1)
(Comment:en)
CL Item
Dose increased (3)
C1707810 (UMLS CUI-1)
(Comment:en)
CL Item
Dose not changed (4)
C0178602 (UMLS CUI-1)
C0443172 (UMLS CUI-2)
(Comment:en)
CL Item
Dose interrupted (5)
C1512900 (UMLS CUI-1)
C0178602 (UMLS CUI-2)
(Comment:en)
CL Item
Not applicable (X)
C1272460 (UMLS CUI-1)
(Comment:en)
Item
Did the subject withdraw from study as a result of this SAE?
text
C0422727 (UMLS CUI [1])
Withdrawal
Code List
Did the subject withdraw from study as a result of this SAE?
CL Item
Yes (Y)
CL Item
No (N)
Item
Is there a reasonable possibility the SAE may have been caused by IP in REDUCE study or prescription dutasteride?
text
C1519255 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Cause of Adverse event
Code List
Is there a reasonable possibility the SAE may have been caused by IP in REDUCE study or prescription dutasteride?
CL Item
Yes (Y)
CL Item
No (N)
Item
If Yes, specify reason
integer
C0566251 (UMLS CUI [1])
Relationship to IP in REDUCE specification
Code List
If Yes, specify reason
CL Item
Prior use of IP in REDUCE study (1)
CL Item
Prescription dutasteride (2)
CL Item
Unable to distinguish (3)
Item Group
SECTION 2: Seriousness (specify reason(s) for considering this a SAE, select all that apply)
C1519255 (UMLS CUI-1)
SAE results in death
Item
[A] Results in death
boolean
C0011065 (UMLS CUI [1])
SAE is life-threatening
Item
[B] Is life-threatening
boolean
C2826244 (UMLS CUI [1])
SAE requires hospitalisation
Item
[C] Requires hospitalisation or prolongation of existing hospitalisation
boolean
C0019993 (UMLS CUI [1])
SAE results in disability/incapacity
Item
[D] Results in disability/incapacity
boolean
C0231170 (UMLS CUI [1])
Congenital anomaly/birth defect
Item
[E] Congenital anomaly/birth defect
boolean
C0000768 (UMLS CUI [1])
Other SAE
Item
[F] Other
boolean
C1519255 (UMLS CUI [1,1])
C1880177 (UMLS CUI [1,2])
Other SAE specification
Item
[F] Other, specify
text
C3845569 (UMLS CUI [1])
Item Group
SECTION 3: Demography data
C1704791 (UMLS CUI-1)
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Item
Sex
text
C0079399 (UMLS CUI [1])
Sex
Code List
Sex
CL Item
Male (Male)
CL Item
Female (Female)
Weight
Item
Weight
float
C0005910 (UMLS CUI [1])
Item Group
SECTION 4: Recurrence of SAE
C0034897 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
Item
If Investigational Product in REDUCE Study or Prescription Dutasteride was Stopped, Did the Reported Event(s) Recur After Further Investigational Product in REDUCE Study or Prescription Dutasteride was Administered?
text
C0034897 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Recurrence of SAE
Code List
If Investigational Product in REDUCE Study or Prescription Dutasteride was Stopped, Did the Reported Event(s) Recur After Further Investigational Product in REDUCE Study or Prescription Dutasteride was Administered?
CL Item
Yes (Yes)
(Comment:en)
CL Item
No (No)
(Comment:en)
CL Item
Unknown at this time (Unknown at this time)
C0439673 (UMLS CUI-1)
(Comment:en)
CL Item
Not applicable (Not applicable)
C1272460 (UMLS CUI-1)
(Comment:en)
Item Group
SECTION 5: Possible Causes of SAE Other Than Investigational Product in REDUCE Study or Prescription Dutasteride
C0392360 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
Disease under study
Item
Disease under study
boolean
C0012634 (UMLS CUI [1])
Medical condition
Item
Medical condition(s)
boolean
C1699700 (UMLS CUI [1])
Medical condition specification
Item
Specify medical condition(s)
text
Lack of efficacy
Item
Lack of efficacy
boolean
C0235828 (UMLS CUI [1])
Withdrawal of investigational product
Item
Withdrawal of investigational product in REDUCE study or prescription dutasteride
boolean
C2349954 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Concomitant Medication
Item
Concomitant Medication(s)
boolean
C2347852 (UMLS CUI [1])
Concomitant Medication specification
Item
Specify concomitant medication(s)
text
C2347852 (UMLS CUI [1])
Activity related to study participation
Item
Activity related to study participation (e.g. procedures)
boolean
C2348568 (UMLS CUI [1])
Other
Item
Other
boolean
C0205394 (UMLS CUI [1])
Other
Item
Other, specify
text
C0205394 (UMLS CUI [1])
Item Group
SECTION 6: RELEVANT Medical Conditions
C0262926 (UMLS CUI-1)
Relevant Medical Conditions
Item
Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE.
text
C0012634 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Date of onset
Item
Date of onset
date
C0574845 (UMLS CUI [1])
Item
Condition Present at Time of the SAE?
text
C0805733 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Condition Present at Time of the SAE
Code List
Condition Present at Time of the SAE?
CL Item
Yes (Y)
CL Item
No (N)
Date of Last Occurrence
Item
If No, Date of Last Occurrence
date
C0011008 (UMLS CUI [1,1])
C2745955 (UMLS CUI [1,2])
Item Group
SECTION 7: Other RELEVANT Risk Factors
C0035648 (UMLS CUI-1)
risk factors
Item
Other relevant risk factors
text
C0035648 (UMLS CUI [1])
Item Group
SECTION 8: RELEVANT Concomitant Medications
C2347852 (UMLS CUI-1)
Drug name
Item
Drug name
text
C0013227 (UMLS CUI [1])
Dose
Item
Dose
float
C3174092 (UMLS CUI [1])
Unit
Item
Unit
text
C1519795 (UMLS CUI [1])
Frequency
Item
Frequency
text
C3476109 (UMLS CUI [1])
Route
Item
Route
text
C0013153 (UMLS CUI [1])
Item
Taken Prior to Study?
text
C2826667 (UMLS CUI [1])
administration prior to study
Code List
Taken Prior to Study?
CL Item
Yes (Y)
CL Item
No (N)
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Stop Date
Item
Stop Date
date
C0806020 (UMLS CUI [1])
Item
Ongoing Medication?
text
C2826666 (UMLS CUI [1])
Ongoing Medication
Code List
Ongoing Medication?
CL Item
Yes (Y)
CL Item
No (N)
Reason for Medication
Item
Reason for Medication
text
C0392360 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Item Group
SECTION 9: Drug Details
C0013227 (UMLS CUI-1)
C1522508 (UMLS CUI-2)
Start Date Investigational Product
Item
Start Date Investigational Product (from REDUCE study)
date
C0808070 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Stop Date Investigational Product
Item
Stop Date Investigational Product (from REDUCE study)
date
C0806020 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Start Date
Item
Start Date Prescription Dutasteride
date
C0808070 (UMLS CUI [1])
Stop Date
Item
Stop Date Prescription Dutasteride
date
C0806020 (UMLS CUI [1])
Item Group
SECTION 10: Details of RELEVANT Assessments
C0220825 (UMLS CUI-1)
Details of Relevant Assessments
Item
Details of Relevant Assessments
text
C1261322 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Item Group
SECTION 11: Narrative Remarks
C0947611 (UMLS CUI-1)
Remarks
Item
Narrative Remarks
text
C0947611 (UMLS CUI [1])
Item Group
Investigator information
C1533716 (UMLS CUI-1)
C0035173 (UMLS CUI-2)
Investigator Signature
Item
Investigator’s signature
text
C2346576 (UMLS CUI [1])
Investigator name
Item
Investigator’s name (print)
text
C2826892 (UMLS CUI [1])
Investigator Signature Date
Item
Date
date
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial